Plasma fibrinogen level may be a possible marker for the clinical response and prognosis of patients with breast cancer receiving neoadjuvant chemotherapy

Abstract

Neoadjuvant chemotherapy has been established as standard treatments for advanced breast cancer among multidisciplinary therapies. A simple and instructive biomarker for the postoperative recurrence and metastasis is needed to evaluate the therapeutic effect. Plasma fibrinogen level has been shown to be associated with tumor progression and poor outcomes in breast cancer patients. This study aims to further evaluate the clinical and prognostic value of plasma fibrinogen level as a biomarker in breast cancer patients receiving neoadjuvant chemotherapy. In this study, data of 67 patients were retrospectively collected and analyzed to identify the relationship between the plasma fibrinogen level and the clinical progression and outcome of these patients. Patients with increased plasma fibrinogen level after neoadjuvant chemotherapy had significantly shorter disease-free survival and overall survival (p < 0.001 and p = 0.001, respectively). In a univariate survival analysis, molecular type (p = 0.0004/p = 0.005), clinical response (p = 0.008/p = 0.015), and changes in plasma fibrinogen level (p = 0.012/p = 0.007) were associated with disease-free survival and overall survival, and all of them, molecular type (p = 0.0003/p = 0.005), clinical response (p = 0.027/p = 0.021), and changes in plasma fibrinogen level (p = 0.035/p = 0.025), were associated with disease-free survival and overall survival in a multivariate survival analysis, respectively. The plasma fibrinogen level was found to be a possible biomarker for clinical response to chemotherapy and postoperative metastasis or death in advanced breast cancer patients who received neoadjuvant chemotherapy.

Preoperative albumin-to-fibrinogen ratio predicts chemotherapy resistance and prognosis in patients with advanced epithelial ovarian cancer

“…The close correlation between inflammation and tumorigenesis may be the main possible explanation for the prognostic role of serum Alb in various malignancies [15]. Elevated serum Fib has also been indicated as a predictor for poor prognosis in esophageal cancer [23], breast cancer [24] and EOC [25]. Increased plasma fib expression contributes to elevated blood coagulability state and promotes the intravasation, adhesion and survival of tumor cells, which results in increased metastatic potential in cancer model [26].…”

Human Plasma-Derived 3D Cultures Model Breast Cancer Treatment Responses and Predict Clinically Effective Drug Treatment Concentrations

“…CA125 is a common blood marker tested in breast cancer and ovarian cancer and it allows for the identification and distinction of the plasma from BCa patients [76,77]. Although the plasma fibrinogen level may be considered a possible marker for the clinical response and prognosis of patients with breast cancer [78], we were able to observe a slightly increased fibrinogen level in our BCa samples, but not enough to be significant in the samples used in our studies. This similarly allows for a more relevant comparison among the HuP3D cultures using either healthy or BCa patient plasma.…”

<p>Prognostic Role of Prothrombin Time Activity, Prothrombin Time, Albumin/Globulin Ratio, Platelets, Sex, and Fibrinogen in Predicting Recurrence-Free Survival Time of Renal Cancer</p>

“… 29 Fibrinogen (FIB) is a kind of clotting factor 30 and has been proven to have prognostic value in breast cancer. 31 Here, we first reported that the PT (%), PT (sec) and FIB could serve as independent risk factors for prediction of RFS.…”